SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 190.43-0.7%Feb 6 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: MulhollandDrive who wrote (7628)9/25/1997 12:39:00 PM
From: Henry Niman   of 32384
 
bp, Actually, I agree with CNBC. Strong Phase II data takes out most of the risk. LGND is in that sweet zone between Phase II results and product approval. I think its pipeline is considerably wider and deeper than AMGN's so I expect it to move now, but to continue because when one product is approved, another will have already generated strong Phase II data. Whatch what happens when the Phase II diabetes data is released (this year, before Panretin approval next year).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News